Show simple item record

dc.contributor.authorPuolakkainen, Tero
dc.contributor.authorMa, Hongqiang
dc.contributor.authorKainulainen, Heikki
dc.contributor.authorPasternack, Arja
dc.contributor.authorRantalainen, Timo
dc.contributor.authorRitvos, Olli
dc.contributor.authorHeikinheimo, Kristiina
dc.contributor.authorHulmi, Juha
dc.contributor.authorKiviranta, Riku
dc.date.accessioned2017-01-24T07:26:38Z
dc.date.available2017-01-24T07:26:38Z
dc.date.issued2017
dc.identifier.citationPuolakkainen, T., Ma, H., Kainulainen, H., Pasternack, A., Rantalainen, T., Ritvos, O., Heikinheimo, K., Hulmi, J., & Kiviranta, R. (2017). Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy. <i>BMC Musculoskeletal Disorders</i>, <i>18</i>(1), Article 20. <a href="https://doi.org/10.1186/s12891-016-1366-3" target="_blank">https://doi.org/10.1186/s12891-016-1366-3</a>
dc.identifier.otherCONVID_26491770
dc.identifier.otherTUTKAID_72682
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/52805
dc.description.abstractBackground: Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to test whether inhibition of activin receptor IIB ligands with or without exercise could improve bone strength in the mdx mouse model for DMD. Methods: Thirty-two mdx mice were divided to running and non-running groups and to receive either PBS control or soluble activin type IIB-receptor (ActRIIB-Fc) once weekly for 7 weeks. Results: Treatment of mdx mice with ActRIIB-Fc resulted in significantly increased body and muscle weights in both sedentary and exercising mice. Femoral μCT analysis showed increased bone volume and trabecular number (BV/TV +80%, Tb.N +70%, P < 0.05) in both ActRIIB-Fc treated groups. Running also resulted in increased bone volume and trabecular number in PBS-treated mice. However, there was no significant difference in trabecular bone structure or volumetric bone mineral density between the ActRIIB-Fc and ActRIIB-Fc-R indicating that running did not further improve bone structure in ActRIIB-Fc-treated mice. ActRIIB-Fc increased bone mass also in vertebrae (BV/TV +20%, Tb.N +30%, P < 0.05) but the effects were more modest. The number of osteoclasts was decreased in histological analysis and the expression of several osteoblast marker genes was increased in ActRIIB-Fc treated mice suggesting decreased bone resorption and increased bone formation in these mice. Increased bone mass in femurs translated into enhanced bone strength in biomechanical testing as the maximum force and stiffness were significantly elevated in ActRIIB-Fc-treated mice. Conclusions: Our results indicate that treatment of mdx mice with the soluble ActRIIB-Fc results in a robust increase in bone mass, without any additive effect by voluntary running. Thus ActRIIB-Fc could be an attractive option in the treatment of musculoskeletal disorders.
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.ispartofseriesBMC Musculoskeletal Disorders
dc.subject.otherbone μCT
dc.subject.otherbone-muscle interactions
dc.subject.otherTGF-βs
dc.subject.otheranimal models
dc.subject.otherexercise
dc.titleTreatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-201701191195
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineLiikuntafysiologiafi
dc.contributor.oppiaineExercise Physiologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.date.updated2017-01-19T10:15:22Z
dc.type.coarjournal article
dc.description.reviewstatuspeerReviewed
dc.relation.issn1471-2474
dc.relation.numberinseries1
dc.relation.volume18
dc.type.versionpublishedVersion
dc.rights.copyright© The Author(s), 2017. This is an open access article under the terms of the Creative Commons Attribution 4.0 International License.
dc.rights.accesslevelopenAccessfi
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1186/s12891-016-1366-3


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s), 2017. This is an open access article under the terms of the Creative Commons Attribution 4.0 International License.
Except where otherwise noted, this item's license is described as © The Author(s), 2017. This is an open access article under the terms of the Creative Commons Attribution 4.0 International License.